Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials.
Seyed Erfan RazaviAkam RamezaniAsma KazemiArmin AttarPublished in: Cardiovascular therapeutics (2022)
Colchicine has shown some molecular and clinical promising results in ACS patients. The lack of effect of colchicine on MI and all-cause mortality can be partly attributed to the limitations of previous studies. Since colchicine is an inexpensive and easy-to-access drug that has shown to be safe in low-dose regimens in the clinical setting; it would be worthy that future large-scale well-designed clinical trials address this issue by resolving the limitations of previous investigations.
Keyphrases
- acute coronary syndrome
- cardiovascular events
- clinical trial
- low dose
- end stage renal disease
- coronary artery disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- antiplatelet therapy
- peritoneal dialysis
- randomized controlled trial
- high dose
- phase ii
- patient reported outcomes
- emergency department
- study protocol
- drug induced
- atrial fibrillation
- electronic health record